Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00257647|
Recruitment Status : Completed
First Posted : November 23, 2005
Last Update Posted : February 18, 2009
|Condition or disease||Intervention/treatment|
|Chronic Myeloid Leukemia||Other: SV40 vectors carrying siRNA|
A novel methodology that facilitates specific silencing of genes has recently been developed. The method is based on the property of small molecules of nucleic acids (RNA) to specifically repress expression of targeted genes. These small interfering RNA (siRNA) molecules were recently demonstrated to repress, in tissue culture cells, one of the two types of the common fusion genes present in CML patients. Those studies showed that treatment with synthetic siRNA inhibited cell growth and increased the sensitivity to imatinib. These findings offer hope that a novel form of gene therapy based on this strategy may improve the treatment outcome of CML patients, particularly when used in combination with other approaches such as the tyrosine kinase inhibitor imatinib that was mentioned above.
Our group has developed an innovative vector that is most suitable to deliver siRNA molecules into human hematopoietic cells with sufficient efficacy. The vector is based on a monkey virus called simian virus 40 (SV40). The viral coat, or capsid, is produced biosynthetically. It was engineered to self-assemble in the test tube around the nucleic acids of choice, and to deliver this DNA or RNA into target cells. This vector is safer than other available viral vectors since all the viral genetic material is excluded from the final product. The vector does not elicit immune response, thus allowing repeated administration.We will start the project by testing the recently published siRNA molecules against one of the fusion genes, and several alternative siRNA molecules that we will design against the other fusion genes. The molecules will be tested for efficacy in tissue culture cell-lines, by measuring repression of the respective fusion gene, reduction in the level of the tyrosine kinase and inhibition of cell growth. The most effective siRNA molecules will be selected for further studies. The vectors will be tested on cell-lines for gene silencing and cell death as before. At the final stage we will test the best vectors for their efficacy in white blood cells obtained from CML patients.
|Study Type :||Observational|
|Estimated Enrollment :||25 participants|
|Official Title:||Use of SV40 siRNA Vectors to Treat CML|
|Study Start Date :||September 2005|
|Actual Study Completion Date :||November 2007|
- Other: SV40 vectors carrying siRNA
in vitro only use of gene therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00257647
|Hadassah Medical Organization|
|Jerusalem, Israel, IL91120|
|Study Chair:||Deborah G Rund, MD||Hadassah Medical Organization|
|Principal Investigator:||Ariella Oppenheim, PhD||Hadassah Medical Organization|